$19.12
+2.8%Tandem Diabetes Care, Inc., a medical device company, designs, develops, and commercializes various products for people with insulin-dependent diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform that comprises t:slim X2 pump, its 300-unit disposable insulin cartridge, and an infusion set. It also provides t:slim X2 insulin with Basal-IQ and control IQ technology; t:slim X2 with G5 Integration; and Tandem Device Updater, a tool that allows users to update their pump's software. In addition, the company offers t:connect, a web-based data management application, which provides a visual way to display diabetes therapy management data from the pump, continuous glucose monitoring, and supported blood glucose meters for users, their caregivers, and their healthcare providers; and Sugarmate, a mobile app for people with diabetes who use insulin. It has development and commercialization agreements with Dexcom, Inc. and Abbott Laboratories. The company was formerly known as Phluid Inc. and changed its name to Tandem Diabetes Care, Inc. in January 2008. Tandem Diabetes Care, Inc. was incorporated in 2006 and is headquartered in San Diego, California.
Last Annual Value
242.72M
3-Year CAGR
14%
5-Year CAGR
19%
10-Year CAGR
25%
| Company | Total Current Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
![]() Tandem Diabetes Care, Inc. NASDAQ:TNDM | 242.72M | 7.5% | 13.0% | 22.7% | |
![]() Tango Therapeutics, Inc. NASDAQ:TNGX | 21.68M | -22.1% | -11.8% | N/A | |
![]() Phathom Pharmaceuticals, Inc. NASDAQ:PHAT | 132.04M | 50.4% | 47.5% | N/A | |
![]() Nurix Therapeutics, Inc. NASDAQ:NRIX | 86.47M | -0.2% | 5.5% | N/A | |
![]() Septerna, Inc. NASDAQ:SEPN | 86.93M | 132.5% | N/A | N/A | |
![]() Fortrea Holdings Inc. NASDAQ:FTRE | 913.30M | 5.5% | 2.0% | N/A | |
![]() UroGen Pharma Ltd. NASDAQ:URGN | 46.42M | 14.1% | 15.7% | 30.9% | |
![]() Kodiak Sciences Inc. NASDAQ:KOD | 45.53M | 3.0% | -6.8% | 33.6% | |
![]() Integra LifeSciences Holdings Corporation NASDAQ:IART | 455.98M | 14.1% | 6.0% | 13.9% | |
![]() EyePoint Pharmaceuticals, Inc. NASDAQ:EYPT | 37.02M | -16.4% | 9.4% | 21.9% |
Continue your TNDM research with focused valuation guides.
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.